Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia

Area of Science:

• Infectious Diseases
• Pharmacology

Background:

• Dalbavancin is a lipoglycopeptide antibiotic with a prolonged half-life, approved for acute bacterial skin and skin structure infections.
• Its efficacy against methicillin-resistant Staphylococcus aureus (MRSA) is established within its approved indications.
• Limited clinical data exist for dalbavancin use in infections beyond its current FDA-approved indications.

Observation:

• A case report details a 28-year-old male with Human Immunodeficiency Virus (HIV) and a history of nonadherence presenting with MRSA pneumonia.
• Initial treatment with vancomycin resulted in subtherapeutic drug concentrations.
• Dalbavancin was administered upon hospital discharge, with the patient readmitted 11 days later due to hemoptysis and shortness of breath.

Findings:

• MRSA was identified in sputum cultures and bronchoalveolar lavage during the initial admission.
• Despite clinical deterioration, subsequent investigations did not reveal evidence of recurrent MRSA infection.
• The patient's history of poor medication adherence was a significant factor in treatment considerations.

Implications:

• This case suggests a potential, albeit unproven, role for dalbavancin in treating non-skin MRSA infections, particularly in nonadherent patients.
• Further research is warranted to explore dalbavancin's utility and safety in treating infections outside its approved indications.
• Understanding treatment challenges in nonadherent patient populations is crucial for optimizing antibiotic therapy outcomes.